ATE326478T1 - Peptidderivat - Google Patents

Peptidderivat

Info

Publication number
ATE326478T1
ATE326478T1 AT01915695T AT01915695T ATE326478T1 AT E326478 T1 ATE326478 T1 AT E326478T1 AT 01915695 T AT01915695 T AT 01915695T AT 01915695 T AT01915695 T AT 01915695T AT E326478 T1 ATE326478 T1 AT E326478T1
Authority
AT
Austria
Prior art keywords
function regulator
regulator
development
present
peptide derivative
Prior art date
Application number
AT01915695T
Other languages
English (en)
Inventor
Chieko Kitada
Naoki Nishizawa
Shuji Hinuma
Masaki Hosoya
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE326478T1 publication Critical patent/ATE326478T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
AT01915695T 2000-03-23 2001-03-22 Peptidderivat ATE326478T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000087114 2000-03-23
JP2000288891 2000-09-19

Publications (1)

Publication Number Publication Date
ATE326478T1 true ATE326478T1 (de) 2006-06-15

Family

ID=26588465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01915695T ATE326478T1 (de) 2000-03-23 2001-03-22 Peptidderivat

Country Status (10)

Country Link
US (1) US7635751B2 (de)
EP (1) EP1270585B1 (de)
JP (1) JP4786047B2 (de)
KR (1) KR20020081466A (de)
CN (1) CN1419563A (de)
AT (1) ATE326478T1 (de)
AU (1) AU2001242749A1 (de)
CA (1) CA2403447A1 (de)
DE (1) DE60119714T2 (de)
WO (1) WO2001070769A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063892A1 (en) * 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1967210A4 (de) * 2005-12-20 2009-11-11 Takeda Pharmaceutical Neue anwendung von apelin
RU2303454C1 (ru) * 2006-06-22 2007-07-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее репродуктивную функцию у женщин, и способ его получения
EP1903052A3 (de) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ Rezeptor-Liganden und deren Verwendung
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US9381229B2 (en) 2011-11-28 2016-07-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
CN104254540A (zh) * 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP3907237A1 (de) 2012-12-20 2021-11-10 Amgen Inc. Apj-rezeptor-agonisten und verwendungen davon
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (de) 2013-07-25 2016-06-01 Novartis AG Cyclische polypeptide zur behandlung von herzinsuffizienz
CN104436158A (zh) * 2013-09-22 2015-03-25 华中科技大学 Apelin-13在治疗糖尿病肾病中的应用
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
EP3273981B1 (de) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
EP3452466B1 (de) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclische triazolverbindungen als agonisten des apj-rezeptors
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541803B1 (de) 2016-11-16 2020-12-23 Amgen Inc. Triazolpyridylverbindungen als agonisten des apj-rezeptors
EP3541802B1 (de) 2016-11-16 2025-01-01 Amgen Inc. Alkylsubstituierte triazolverbindungen als agonisten des apj-rezeptors
EP3541792B1 (de) 2016-11-16 2020-12-23 Amgen Inc. Triazol-furan-verbindungen als agonisten des apj-rezeptors
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3788037A1 (de) 2018-05-01 2021-03-10 Amgen Inc. Substituierte pyrimidinone als agonisten des apj-rezeptors
WO2026007693A1 (zh) * 2024-07-05 2026-01-08 浙江大学 Apelin-13多肽突变体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118372T3 (es) * 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
CN1283228A (zh) * 1997-12-24 2001-02-07 武田药品工业株式会社 多肽、其生产方法及应用
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative

Also Published As

Publication number Publication date
CA2403447A1 (en) 2001-09-27
US7635751B2 (en) 2009-12-22
DE60119714T2 (de) 2006-09-07
JP4786047B2 (ja) 2011-10-05
AU2001242749A1 (en) 2001-10-03
WO2001070769A1 (fr) 2001-09-27
US20040116336A1 (en) 2004-06-17
JP2002167397A (ja) 2002-06-11
EP1270585A1 (de) 2003-01-02
EP1270585A4 (de) 2004-12-15
DE60119714D1 (de) 2006-06-22
EP1270585B1 (de) 2006-05-17
CN1419563A (zh) 2003-05-21
KR20020081466A (ko) 2002-10-26

Similar Documents

Publication Publication Date Title
DE60119714D1 (de) Peptidderivat
SE9901379D0 (sv) Receptor structures
SE8904087D0 (sv) Peptide derivates
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
ATE274064T1 (de) Multimere proteine
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69906108D1 (de) Peptid-derivat
DE69636437D1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
MXPA02008239A (es) Gen humano de la esquizofrenia.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
EP0635016A4 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden.
EP0815240A4 (de) Neue menschliche proteine, die cyclinebhängigen kinasen ähneln, sowie methoden zu deren verwendung
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken
WO2001064876A3 (en) Human schizophrenia gene
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
DK0972781T3 (da) Protein S-polypeptider og anvendelser deraf
WO2003044160A3 (en) Novel molecules of the card related protein family and uses thereof
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.
HK1027837A (en) Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties